PHARMACEUTICAL 2022

Madrigal Pharmaceuticals INC
Rank 393 of 471



PHARMACEUTICAL 2022

Madrigal Pharmaceuticals INC
Rank 393 of 471

The relative strengths and weaknesses of Madrigal Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Madrigal Pharmaceuticals INC compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 4.3% points.The greatest weakness of Madrigal Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 130% points.

The company's Economic Capital Ratio, given in the ranking table, is 141%, being 134% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	271,684
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	76,838
Liabilities, Non-Current	387
Other Assets	797
Other Compr. Net Income	-127
Other Expenses	205,164
Other Liabilities	0
Other Net Income	363
Other Revenues	273
Property and Equipment	851
Research and Development	205,164
Selling, General and Administrative Expense	37,318

Output Variable	Value in 1000 USD
Assets	273,332
Liabilities	77,225
Expenses	447,646
Revenues	273
Stockholders Equity	196,107
Net Income	-447,010
Comprehensive Net Income	-447,074
BaseVar	399,483
ECR before LimitedLiability	-11%
Economic Capital Ratio	141%